Randox, a leading global diagnostics company and world leader in the development of diagnostic biochips, today announced the completion of its acquisition of Cellix Limited, a Dublin-based company that develops microfluidic tools and impedance flow cytometers for cell analysis.
The acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space aligning with their commitment to personalised medicine and improved preventative healthcare.
“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians,” said Dr Peter FitzGerald, Managing Director of Randox Laboratories. “We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows resulting in better outcomes for patients.”
Vivienne Williams, CEO of Cellix added, “Our team is very excited to be joining forces with Randox to scale access to our technology in the broader scientific community. Cellix’s dedicated team has worked hard developing impedance-based cytometry for cell analysis supported through programs including the Disruptive Technology Innovation Fund. With Randox’s strong global presence and dedication to R&D, we are looking forward to continuing development of our technology and expanding our customer footprint.”
A global market leader within the in vitro diagnostics industry, Randox Laboratories develops innovative diagnostic solutions for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs and life sciences. With offices and distribution in over 145 countries, Randox offers customers improved efficiency, quality, cost-effectiveness and flexibility. Randox is committed to revolutionising healthcare on a global scale. With over 2,500 employees globally, Randox is dedicated to meeting your testing needs. For more information, please visit www.randox.com.
Cellix is a developer of microfluidic tools and impedance flow cytometers for cell analysis and sorting. Customers are in life science research, cell and gene therapy discovery, development and manufacturing. With an established product portfolio of microfluidic solutions for life science research; Cellix recently launched it’s first product in flow cytometry: the Inish Analyser is a microfluidic impedance-based flow cytometer for cell counting, cell viability and cell membrane analysis for transfection efficiencies. Cellix is an Enterprise Ireland client company and a beneficiary of the Disruptive Technology Innovation Fund.